Session N.00146

42. Emerging perspectives in the treatment of paediatric MDR-TB

Saturday, 01 November 2014, 09:15 - 11:15

Room 115

Type: Symposium
Track: Adult and Child Lung Health
Topic: Other

Description:
MDR-TB in children is a globally emerging problem. Current regimens are long, toxic and typically require long hospital admission. Data on the optimal use of 2nd line drugs and novel treatment strategies are urgently needed for children. This symposium aims to address practical aspects of the management of children and adolescents with DR-TB from geographically diverse settings. Emerging data on the pharmacokinetics and safety of existing 2nd line drugs and novel TB drugs will be shared. Qualitative data on children’s experience of MDR-TB treatment will be presented.

Target audience:
Intended target audience: NTP personnel, paediatric TB care providers, clinical researchers, regulatory, funders and pharma.

Objectives:
1. To provide evidence on management and treatment outcomes in paediatric-MDR-TB from diverse settings
2. To provide new evidence on the optimal use of existing 2nd line TB drugs in children with MDR-TB
3. To share early experiences in the clinical evaluation of novel TB drugs in children with MDR-TB
4. To provide data on the psychosocial impact of MDR-TB in children

Keywords:
MDR-TB; children; adolescents; treatment; drugs; PK, safety; novel; evaluation; psychosocial

Coordinator(s):
Anneke Hesseling (South Africa), James Seddon (UK)

Chair(s):
Hendrik Simon Schaaf (South Africa), Jennifer Furin (USA)

Presentations:
09:15 - 09:30 Patient and caregiver perspectives of MDR-TB treatment in children
Caroline Franck (UK)
09:35 - 09:50 Treatment outcomes in children with paediatric MDR-TB in Georgia
Medea Gegia (Georgia)
09:55 - 10:10 Experiences in treating children with MDR-TB in India
Sangeeta Sharma (India)
10:15 - 10:35 The pharmacokinetics of moxifloxacin in children with MDR-TB
Stephanie Thee (Germany)
10:40 - 10:55 Early experiences in the evaluation of a novel TB drug in children
Jeffrey Hafkin (USA)
11:00 - 11:15 Discussion